NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

HIV Prevention Counseling for Men Who Have Sex With Men

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-09-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 4350

Registration Number: NCT00000931

Locations: 🇺🇸
San Francisco Dept of Hlth / AIDS Office, San Francisco, California, United States
🇺🇸
Denver Dept of Public Health / HIVNET, Denver, Colorado, United States
🇺🇸
New York Blood Ctr, Bronx, New York, United States

and more 3 locations

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-09-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 28

Registration Number: NCT00000795

Locations: 🇺🇸
Johns Hopkins Univ / Ctr for Immunological Research, Baltimore, Maryland, United States

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

Phase 1

Completed

Conditions: HIV Infections
Tuberculosis

First Posted Date: 2001-08-31

Last Posted Date: 2008-09-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 44

Registration Number: NCT00004736

Locations: 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸
Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States

and more 7 locations

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-09-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 80

Registration Number: NCT00001132

Locations: 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸
Emory Univ, Atlanta, Georgia, United States
🇺🇸
Cook County Hosp, Chicago, Illinois, United States

and more 27 locations

A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-08-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT00000699

Locations: 🇺🇸
George Washington Univ Med Ctr, Washington, District of Columbia, United States

A Study of d4T in Patients With AIDS or AIDS-Related Complex Who Cannot Take AZT

Phase 1

Terminated

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-08-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 35

Registration Number: NCT00000686

Locations: 🇺🇸
Cornell Univ Med Ctr, New York, New York, United States

A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-08-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 25

Registration Number: NCT00000669

Locations: 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸
The Regional Medical Ctr, Memphis, Memphis, Tennessee, United States
🇺🇸
Univ TX Health Science Ctr, Houston, Texas, United States

and more 2 locations

A Study of BMY-27857 in Patients With AIDS or AIDS Related Complex

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-08-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT00000988

Locations: 🇺🇸
Mount Sinai Med Ctr, New York, New York, United States
🇺🇸
Cornell Univ Med Ctr, New York, New York, United States

A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome

Phase 1

Completed

Conditions: Cachexia
HIV Infections
HIV Wasting Syndrome

First Posted Date: 2001-08-31

Last Posted Date: 2008-08-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 56

Registration Number: NCT00000737

Locations: 🇺🇸
Denver Public Health Dept, Denver, Colorado, United States
🇺🇸
Univ of Illinois, Chicago, Illinois, United States
🇺🇸
Univ of Kansas School of Medicine, Wichita, Kansas, United States

and more 6 locations

A Study of Dideoxycytidine Plus Zidovudine in the Treatment of AIDS or Advanced AIDS Related Complex (ARC)

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-08-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 68

Registration Number: NCT00000978

Locations: 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy